Market Research Logo

Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2018

Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2018 provides an overview of Relapsed Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2018*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Figure 3: Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Table Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
        • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
        • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
        • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
        • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
        • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials
    • Table Figure 9: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018*
    • Table Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials
    • Table Figure 12: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018*
    • Table Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by Phase
    • Table Figure 15: Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2018*
    • In Progress Trials by Phase
      • Table Figure 16: Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
      • Table Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Clinical Trials by Trial Status
    • Table Figure 17: Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by End Point Status
    • Table Figure 18: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
    • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
    • Table Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Prominent Sponsors
    • Table Figure 21: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials
      • Table Figure 22: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
      • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Prominent Drugs
    • Table Figure 23: Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
    • Table Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Latest Clinical Trials News on Relapsed Multiple Myeloma
    • Jun 17, 2018: Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma
    • Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm
    • Jun 15, 2018: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma
    • Jun 11, 2018: FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label
    • Jun 01, 2018: Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
    • Jun 01, 2018: Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
    • Jun 01, 2018: Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
    • May 25, 2018: Glenmark Pharmaceuticals Announces Poster Presentation on GBR 1342 at 2018 ASCO Annual Meeting
    • May 17, 2018: PharmaMar Announces Data Presentations on its molecule Plitidepsin at ASCO 2018
    • May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association
    • May 17, 2018: Genmab Announces Abstracts to be Presented on Daratumumab at 23rd EHA Annual Congress
    • May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting
    • May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018
    • May 16, 2018: bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
    • May 16, 2018: Janssen to Present Data on DARZALEX at ASCO 2018
    • May 16, 2018: Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions
    • Apr 30, 2018: Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS (carfilzomib) Label
    • Apr 28, 2018: BMS Phase 2 trial of the efficacy and safety of Elotuzumab
    • Apr 28, 2018: BMS Phase 2 single arm study of safety of Elotuzumab
    • Apr 25, 2018: Genmab to Present Data on Daratumumab at 2018 ASCO Annual Meeting
    • Apr 25, 2018: Incyte to Present Data from Phase 1 Study of Ruxolitinib at the 2018 ASCO Annual Meeting
    • Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin
    • Apr 18, 2018: Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting
    • Apr 17, 2018: Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report